ArticleAnnals of medicine and surgery (2012)2025
Genome-wide methylation and copy number variation analysis of medulloblastoma in a Saudi Arabian pediatric population.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medulloblastoma represents the most common malignant brain tumor in children, characterized by distinct molecular variants that suggest varied prognosis and treatment responses. Genome-wide methylation profiling could be used to characterize these aforementioned variants. Infinium EPIC [850k] analyzes 850 000 sites within the genome of the medulloblastoma to establish the unique pattern of DNA methylation at CPG sites. This study conducted a genome-wide methylation analysis on six pediatric medulloblastoma samples using Illumina Human Methylation 850 K BeadChip arrays. We integrated methylation data with copy number variation (CNVs) profiles to assign molecular subgroups (WNT, SHH, Group 3, and Group 4) to our medulloblastoma cases. Three cases were successfully classified using the EPIC arrays, while the rest of the cases were partially assigned. Group 3-4 tumors were the most common molecular subgroup identified in two cases with a methylation score of >0.9 and in one case with a score of 0.62. An SHH molecular group was also represented. Furthermore, CNV profiles were provided for all cases. Patients classified with Group 3-4 tumors were shortly deceased after diagnosis, while all the remaining patients were alive and well after 48-108 months of follow-up. Group 3-4 tumors were the most common group in this limited series of our patients with medulloblastoma and contributed to mortality in three patients. This study highlights the use of genome-wide methylation analysis and CNVs in categorizing pediatric medulloblastoma in the country and presents a new tool in diagnostic neuro-oncology, prognostic classification, and personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.